Skip to content
The Hip Signal
A Phoenix mechanism notebook

The Hip Signal

Clear answers about a sore hip and blood-based care

What questions come up before choosing hip care? People ask what blood-based care may do. They also ask when an exam comes first.

You'll find direct answers here.

How does regenerative medicine work?

Regenerative medicine is a name for care made from your blood or bone marrow. PRP is the part of your blood prepared to hold more platelets. Platelets are tiny blood parts that help stop bleeding. They release natural substances near the sore area. That may ease soreness, but it doesn't make a new hip.

Can PRP grow new hip cartilage?

Hip research hasn't shown that PRP grows new cartilage. Cartilage coats your joint bones so they glide smoothly. Your soreness may ease while an X-ray stays unchanged. Feeling better isn't proof that this tissue grew back.

Do the cells stay in the joint?

This question usually means cells taken from bone marrow. Research hasn't shown that they remain in the hip and turn into lasting cartilage. Blood-based care may ease soreness for some people. Research hasn't found replacement tissue after this care.

Could less irritation explain why I feel better?

Yes, that could explain some relief. Rest and shorter activity may help too. Even the attention given during a clinic visit can change how you feel. That's why relief alone can't show what helped most.

What does regenerative medicine mean for my hip?

It's a broad name for procedures using blood or bone marrow. The term describes what the clinic hopes to help. It can't prove that worn tissue will rebuild. Ask what material is used and what daily change you may notice.

Can I avoid hip replacement?

Sometimes surgery can wait. Gentler activity, strength work, a cane, and other care may keep you moving. Pain at rest or a large loss of movement deserves a surgeon's view. Asking for that view doesn't mean you've chosen surgery.

Where can I discuss regenerative medicine in Phoenix?

The nearest office depends on your part of Phoenix. Banner Estrella suits many west-side trips. Another area may put Scottsdale or Chandler closer. Bring notes about walking, sleep, and stairs. QC Kinetix can examine your hip and discuss regenerative treatments prepared at the clinic from your blood or bone marrow.

Sources

  1. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

    US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

  2. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to.

    Caplan AI, et al. — Mesenchymal Stem Cells: Time to Change the Name!. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.17-0051.

  3. A concise review of mesenchymal stem cells for functional cartilage tissue engineering sets out the underlying problem: articular cartilage is avascular and has very limited intrinsic repair capacity, which is precisely why engineered and cell-based approaches are being pursued - and why building tissue that matches native articular cartilage in composition and mechanical function remains an unsolved engineering problem rather than a delivered clinical product.

    Tan AR, et al. — Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.16-0271.

  4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

    Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

  5. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

    Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

  6. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.

    American Academy of Orthopaedic Surgeons — Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.. AAOS, 2017.

A clinic visit starts with an exam of your hip

Your first QC Kinetix consultation costs nothing. Clinic staff examine you and discuss regenerative treatments made from your blood or bone marrow, the soft center within a bone.

Book a free consultation